This inventor holds 2 USPTO granted patents. Top assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai. Active years: 1985-1987.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Houya, JP (1985)
- Hoya, JP (1987)
Company Filing History:
Years Active: 1985-1987
Title: Wataru Tanaka: Innovator in Carcinostatic Derivatives
Introduction
Wataru Tanaka is a notable inventor based in Houya, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel derivatives with potential therapeutic applications. With a total of 2 patents to his name, Tanaka's work focuses on compounds that exhibit high carcinostatic activity.
Latest Patents
Tanaka's latest patents include innovative compounds that are expected to have a substantial impact on cancer treatment. One of his inventions is a novel 4'-demethyl-4-epipodophyllotoxin derivative. This invention relates to a compound characterized by a specific formula, wherein R₁ is a lower alkyl group, and X₁ and X₂ are hydroxyl or amino groups. The other patent involves derivatives of 4'-demethyl-4-epipodophyllotoxin, which are represented by a general formula and are noted for their high carcinostatic activity and water solubility.
Career Highlights
Wataru Tanaka is associated with Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, where he continues to advance his research in medicinal chemistry. His work is recognized for its potential to contribute to the development of effective cancer treatments.
Collaborations
Tanaka has collaborated with esteemed colleagues in his field, including Hamao Umezawa and Tomio Takeuchi. These collaborations have likely enriched his research and contributed to the innovative nature of his patents.
Conclusion
Wataru Tanaka's contributions to the field of medicinal chemistry, particularly through his innovative patents, highlight his role as a significant inventor. His work on carcinostatic derivatives showcases the potential for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile